| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2024 ( Subtotal = $780,148 ) |
| | 2024 | 2024 | IMMUNOPHOTONICS INC | 4340 DUNCAN AVE | SAINT LOUIS | MO | 63110-1110 | SAINT LOUIS CITY | USA | R44CA257683 | Development of polymeric synthetic biomaterial IP-001 to potentiate asystemic immunotherapy of hepatocellular carcinoma via thermal ablation | 001 | 3 | NIH | 7/29/2024 | $780,148 |
| | 2024 | 2023 | IMMUNOPHOTONICS INC | 4340 DUNCAN AVE | SAINT LOUIS | MO | 63110-1110 | SAINT LOUIS CITY | USA | R44CA257683 | Development of polymeric synthetic biomaterial IP-001 to potentiate asystemic immunotherapy of hepatocellular carcinoma via thermal ablation | 000 | 2 | NIH | 10/20/2023 | $0 |
|
| Issue Date FY: 2023 ( Subtotal = $1,219,852 ) |
| | 2023 | 2023 | IMMUNOPHOTONICS INC | 4340 DUNCAN AVE | SAINT LOUIS | MO | 63110-1110 | SAINT LOUIS CITY | USA | R44CA257683 | Development of polymeric synthetic biomaterial IP-001 to potentiate asystemic immunotherapy of hepatocellular carcinoma via thermal ablation | 000 | 2 | NIH | 9/15/2023 | $1,219,852 |
|
| Issue Date FY: 2021 ( Subtotal = $400,000 ) |
| | 2021 | 2021 | IMMUNOPHOTONICS, INC. | 4340 DUNCAN AVE STE 212 | SAINT LOUIS | MO | 63110-1110 | SAINT LOUIS CITY | USA | R44CA257683 | Development of polymeric synthetic biomaterial IP-001 to potentiate asystemic immunotherapy of hepatocellular carcinoma via thermal ablation | 001 | 1 | NIH | 9/21/2021 | $0 |
| | 2021 | 2021 | IMMUNOPHOTONICS, INC. | 4340 DUNCAN AVE STE 212 | SAINT LOUIS | MO | 63110-1110 | SAINT LOUIS CITY | USA | R44CA257683 | Development of polymeric synthetic biomaterial IP-001 to potentiate asystemic immunotherapy of hepatocellular carcinoma via thermal ablation | 000 | 1 | NIH | 8/13/2021 | $400,000 |
|
|
